Neuroventi signed an MOU for cooperative research with a micropig-based biotechnology company.

We have signed a memorandum of understanding (MOU) for joint research with Apurus (formerly Medikinetics), a company that develops micropig (mini-pig)-based xeno-organ and xeno-cell therapies.

Through this MOU, our company and the two institutions,

△ Establishment of micropig-based brain disease animal models (autism, ADHD) △ Development of behavioral analysis methods for core and accompanying symptoms △ Development of behavioral analysis devices and devices △ Mutual cooperation will be carried out in all other areas where cooperation is possible, and at the same time, long-term partnerships and We aim for mutual growth.

For the development of autism treatment, we cooperate in the development of brain disease-related animal models using Micropig and the standardization of drug efficacy evaluation systems, and maximize the synergy effect of human and academic information exchange and joint research to derive optimized research results and put them to practical use. plan to work hard.

In addition, based on long-term strategic alliances, we will strengthen cooperative relationships for the commercialization of new drug pipelines owned by each institution.

Based on the results of this collaborative research, we expect to establish animal disease models optimized for the development of drugs for brain development disorders, including autism, the only neurological disease for which there is no cure, and to secure development capabilities for commercialization.